Topical Steroids and Cyclosporin-A for COVID-19 Keratoconjunctivitis

Ameera Gamal Abdelhameed

Status: Unknown

Conditions: Keratonjunctivitis

Treatments: Drug: topical steroids and cyclosporin-A

Study type: Interventional

Funder types: Other

Identifiers

NCT04451239

COVID-19 keratoconjunctivitis

Details and patient eligibility

About

To explore the feasibility of combined topical corticosteroid and topical cyclosporine-A in COVID-19 patients with acute keratoconjunctivitis.

Full description

COVID-19 patients presenting with acute keratoconjunctivitis will be treated with Topical 1% prednisolone acetate fourTimes daily for 7 days as initial treatment, non-preserved artificial tears four times daily and cyclosporin A 0.5% four times daily .

Twelve patients with COVID-19 Keratoconjunctivitis will be enrolled in this open-label study. Symptoms and findings of the patients before and after treatment were recorded.

Enrollment: 12 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• COVID-19 Patients with keratoconjunctivitis

Exclusion criteria

• associated ocular pathology or disease
• other causes of keratoconjunctivitis for example allergic or herpetic

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

12 participants in 1 patient group

COVID-19 keratoconjunctivitis

Other group

Description:

cases will receive topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .

Treatment:

Drug: topical steroids and cyclosporin-A